trending Market Intelligence /marketintelligence/en/news-insights/trending/dqtyf11osnpcgzi15aeana2 content esgSubNav
In This List

Checkpoint's lung cancer therapy shows anti-tumor activity in early-stage trial

Video

S&P Capital IQ Pro | Powering Your Edge

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


Checkpoint's lung cancer therapy shows anti-tumor activity in early-stage trial

Checkpoint Therapeutics, Inc. said its lung cancer drug was well-tolerated and demonstrated anti-tumor activity in an early stage trial.

The phase 1/2 trial is evaluating CK-101, also known as RX518, in 19 patients with non-small cell lung cancer, the most common type of lung cancer.

Anti-tumor activity was particularly observed in patients having a mutation in the epidermal growth factor receptor, or EGFR, protein who had never undergone treatment before. Six out of these eight patients saw a reduction in tumor size but did not see their disease go away completely.

In six patients whose disease had spread to the brain, three patients saw a reduction in their cancer. A higher response rate was seen in patients who had a larger concentration of the drug in their bodies, with six out of 11 patients seeing tumor size reduction.

The company said there were no dose-limiting toxicities or treatment-related serious side effects.

Checkpoint said in a Sept. 6 news release that it plans to begin a phase 3 trial in EGFR mutation-positive non-small cell lung cancer patients who have not had prior treatment in 2019.